» Articles » PMID: 12535224

Immune Parameters Relevant to Neural Xenograft Survival in the Primate Brain

Overview
Specialty General Surgery
Date 2003 Jan 22
PMID 12535224
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The lack of supply and access to human tissue has prompted the development of xenotransplantation as a potential clinical modality for neural cell transplantation. The goal of the present study was to achieve a better understanding of the immune factors involved in neural xenograft rejection in primates. Initially, we quantified complement mediated cell lysis of porcine fetal neurons by primate serum and demonstrated that anti-C5 antibody treatment inhibited cell death. We then developed an immunosuppression protocol that included in vivo anti-C5 monoclonal antibody treatment, triple drug therapy (cyclosporine, methylprednisolone, azathioprine) and donor tissue derived from CD59 or H-transferase transgenic pigs and applied it to pig-to-primate neural cell transplant models. Pre-formed alphaGal, induced alphaGal and primate anti-mouse antibody (PAMA) titers were monitored to assess the immune response. Four primates were transplanted. The three CD59 neural cell recipients showed an induced anti-alphaGal response, whereas the H-transferase neural cell recipient exhibited consistently low anti-alphaGal titers. Two of these recipients contained surviving grafts as detected by immunohistochemistry using selected neural markers. Graft survival correlated with high dose cyclosporine treatment, complete complement blockade and the absence of an induced PAMA response to the murine anti-C5 monoclonal antibodies.

Citing Articles

Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5.

Zelek W, Menzies G, Brancale A, Stockinger B, Morgan B Immunology. 2020; 161(2):103-113.

PMID: 32557571 PMC: 7496778. DOI: 10.1111/imm.13228.


Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives.

Wianny F, Vezoli J Primate Biol. 2020; 4(2):185-213.

PMID: 32110706 PMC: 7041537. DOI: 10.5194/pb-4-185-2017.


Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Sonntag K, Song B, Lee N, Jung J, Cha Y, Leblanc P Prog Neurobiol. 2018; 168:1-20.

PMID: 29653250 PMC: 6077089. DOI: 10.1016/j.pneurobio.2018.04.005.


Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.

Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A Stem Cells. 2013; 31(8):1548-62.

PMID: 23666606 PMC: 3775937. DOI: 10.1002/stem.1415.


Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation.

Martin C, Plat M, Nerriere-Daguin V, Coulon F, Uzbekova S, Venturi E Transgenic Res. 2005; 14(4):373-84.

PMID: 16201404 DOI: 10.1007/s11248-004-7268-4.